Strongest evidence: The most robust research supports Lactobacillus salivarius UCC118 for improving insulin sensitivity (high evidence strength, 6 of 6 studies beneficial, moderate effect size) and reducing inflammation (moderate evidence strength, 8 of 8 studies beneficial, moderate effect size). Evidence for reducing the prevalence of gestational diabetes mellitus is also moderate (4 studies, all beneficial, with two meta-analyses reporting 29–48% risk reductions). All three outcomes are studied predominantly in pregnant women and women with gestational diabetes. No specific effective dose ranges have been consistently reported.
Mixed or weaker evidence: Several outcomes show preliminary or very-low-strength evidence. Improved gastrointestinal health (10 studies, all beneficial) and improved glucose metabolism (4 studies, all beneficial) rely largely on reviews and meta-analyses that do not isolate this specific strain or lack statistical significance. Outcomes such as reduced infection risk, reduced insulin levels, improved immune function, immune modulation, and gut microbiota changes are supported by only 2–5 studies each, with evidence strength rated low or very low. Notably, for reduced insulin levels, one RCT found neutral results while two meta-analyses showed benefit, creating a discrepancy.
Effective dose patterns: No cross-cutting effective dose range can be derived. The majority of studies did not report the specific dose of Lactobacillus salivarius UCC118, as many used multi-strain probiotic formulas or synbiotics, making it impossible to isolate a dose–response relationship for this strain alone.
Population insights: The most consistent and strongest evidence comes from pregnant women, particularly those with gestational diabetes mellitus. Benefits for insulin sensitivity, inflammation, glucose metabolism, and GDM prevalence are largely confined to this population. Evidence in other groups — such as athletes, multiple sclerosis patients, or individuals with obesity — is limited to small numbers of studies or review articles without original data.
Notable caveats: (1) Publication bias is a recurring concern across multiple syntheses — null results may be underreported. (2) Many studies test multi-strain probiotics or synbiotics, so the specific contribution of L. salivarius UCC118 cannot be isolated. (3) For several outcomes, the evidence consists entirely of narrative reviews or meta-analyses of general probiotics, not original human trials of this specific strain. (4) Statistical significance was not reached in many studies, suggesting effects may be smaller than the uniformly positive direction implies.